PAH
Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib
May 7, 2024Research and Development Chiesi, Chronic Diseases, Gossamer Bio, PAH, PH-ILD, collaboration
US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …
United Therapeutics buys Arena’s hypertension drug ralinepag in deal worth $1.2 billion
November 16, 2018Medical Communications Arena, PAH, United Therapeutics, deal sales, hypertension
US pharma firm United Therapeutics has agreed to by Arena Pharmaceuticals experimental pulmonary arterial hypertension (PAH) drug ralinepag in a …
Actelion’s Uptravi goes on sale
January 5, 2016Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag
Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …
Pfizer’s Revatio extends Europe PAH licence
May 9, 2011Sales and Marketing PAH, Pfizer, pulmonary arterial hypertension, revatio
Pfizer’s Revatio has been approved by European regulators for the treatment of pulmonary arterial hypertension (PAH) in children.The European Commission has …
Pfizer withdraws hypertension drug Thelin
December 14, 2010Sales and Marketing PAH, Pfizer, Thelin, liver damage, liver toxicity, patient safety, pulmonary arterial hypertension, sitaxentan
Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …
Pfizer adds another product to its PAH franchise
May 14, 2010Research and Development Ergonex, PAH, Pfizer, Thelin, revatio, terguride, viagra
Pfizer has signed an agreement to acquire terguride, a drug for pulmonary arterial hypertension (PAH) currently in phase II testing, …
Latest content
Five Facts about cardiovascular disease
